|
[1]GANEM D, PRINCE AM.Hepatitis B virus infection--naturat history and clinical consequences[J].N Engl J Med, 2004, 350 (11) :1118-1129.
|
|
[2]World Health Organization.Hepatitis B[EB/OL]. (2008-08) [2010-12-09]http//www.who.int/mediacentre/factsheets/fs204/en/.
|
|
[3]LIANG X, BI S, YANG W, et al.Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaceination[J].Vaccine, 2009, 27 (47) :6550-6557.
|
|
[4]LIANG X, BI S, YANG W, et al.Evaluation of the impact of hepatitis B vaccination among children bom during 1992-2005 in China[J].J Infect Dis, 2009, 200 (1) :39-47.
|
|
[5] LU FM, ZHUANG H.Management of hepatifis B in China[J].Chin Med J (Engl) , 2009, 122 (1) :3-4.
|
|
[6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南2010年版[J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.
|
|
[7]YANG M, RAO HY.Key points of the AASLD's guidelines on hepatitis C diagnosis and treatment[J].J Clin Hepatol, 2013, 29 (2) :9-14. (in Chinese) 杨明, 饶慧瑛.美国肝病学会丙型肝炎诊治指南要点[J].临床肝胆病杂志, 2013, 29 (2) :9-14.
|
|
[8]KETENKO SV, GALLAGHER G, BAURIN VV, et al.IFN-lambads mediate antiviral protection through a distinct class II cytokine receptor complex[J].Nat Immunol, 2003, 4 (1) :69-77.
|
|
[9]UZG, MONNERON D.IL-28 and IL-29:newcomers to the interferon family[J].Biochimie, 2007, 89 (6-7) :729-734.
|
|
[10]ANK N, WEST H, PALUDAN SR.IFN-lambda:novel antiviral cytokine[J].J Interferon Cytokine Res, 2006, 26 (6) :373-379.
|
|
[11]O'BRIEN TR.Interferon-alfa, Interferon-lambda and hepatitis C[J].Nat Genet, 2009, 41 (10) :1048-1050.
|
|
[12]IADONATO SP, KAEZE MG.Genomics:Hepatitis C virus gets personal[J].Nature, 2009, 461 (7262) :357-358.
|
|
[13]THOMAS DL, THIO CL, MARTIN MP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.
|
|
[14]GE D, FELLAY J, THOMPSON AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment—induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.
|
|
[15]RAUCH A, KUTALILC Z, DESCOMBES P, et al.Genetic Variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide associationstudy[J].Gastroentemlogy, 2010, 138 (4) :1338-1345.
|
|
[16]MANGIA A, THOMPSON A, SANTORO R, et al.An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3patients who do not achieve a rapid virologic response[J].Gastroenterology, 2010, 139 (3) :821-827.
|
|
[17]MCCARTHY JJ, LI JH, THOMPSON A, et al.Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin[J].Gastroenterology, 2010, 138 (7) :2307-2314.
|
|
[18]REMBECK K, ALSIA, CHRISTENSEN PB, et al.Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3[J].PLoS One, 2012, 7 (1) :e29370.
|
|
[19]JACOBSON IM, MCHUTCHISON JG, DUSHEIKO G, et al.Telaprevir for previously untreated chronic hepatitis C virus infection[J].N Engl J Med, 2011, 364 (25) :2405-2416.
|
|
[20]HONDA M, SAKAI A, YAMASHITA A, et al.Hepatic ISG exprsssion is associated with genetic variation in interleukin 28B and the outcome of interferon therapy for chronic hepatitis C[J].Gastroenterology, 2010, 139 (2) :499-509.
|
|
[21]URBAN TJ, THOMPSON AJ, BRADRICK SS, et al.IL28B genotype is associated with differential expression of intrahepatic interferon, stimulated genes in patients with chronic hepatitis C[J].Hepatology, 2010, 52 (6) :1888-1896.
|
|
[22]SAITO H, ITO K, SUGIYAMA M, et al.Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients[J].Hepatol Res, 2012, 42 (10) :958-965.
|
|
[23]BOCHUD PY, BIBERT S, KUTALIK Z, et al.IL28B alleles associated with poor Hepatitis C clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes[J].Hepatology, 2012, 55 (2) :384-394.
|
|
[24]MARABITA F, AGHEMO A, DE NICOLA S, et al.Genetic variation in the interleukin-28B gene is not associated with fibrosisi progression in patients with chronic hepatitis C and known date of infection[J].Hepatology, 2011, 54 (4) :1127-1134.
|
|
[25]AL-QAHTANI AA, AL-ANAZI MR, ABDO AA, et al.Genetic variation in interleukin 28 B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients[J].Liver Int, 2014, 34 (7) :e208-e216.
|
|
[26]CHENG L, SUN X, TAN S, et al.Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients[J].Hepatol Res, 2014, 44 (9) :1000-1007.
|
|
[27]ZHANG Q, LAPALUS M, ASSELAH T, et al.IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients[J].J Virol Hepat, 2014, 21 (7) :525-532.
|
|
[28]CHEN J, WANG L, LI Y, et al.Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese[J].PLoS One, 2012, 7 (12) :e50787.
|
|
[29]LEE IC, LIN CH, HUANG YH, et al.IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B[J].PLoS One, 2013, 8 (2) :e58071.
|
|
[30]TAMORI A, KAWADA N.HLA classⅡassociated with outcomes of hepatitis B and C infections[J].World J Gastroenterol, 2013, 19 (33) :5395-5401.
|
|
[31]KIM SU, SONG KJ, CHANG HY, et al.Association between IL28B Polymorphisms and spontaneous clearance of hepatitis B virus infection[J].PLoS One, 2013, 8 (7) :e69166.
|
|
[32]GARCIA-SAMANIEGO J, ROMERO M, GRANADOS R, et al.Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C[J].World J Gastroenterol, 2013, 19 (12) :1943-1952.
|
|
[33]LI W, JIANG Y, JIN Q, et al.Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population[J].Liver Int, 2011, 31 (8) :1118-1126.
|
|
[34]MARTIN MP, QI Y, GOEDERT JJ, et al.IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection[J].J Infect Dis, 2012, 202 (11) :1749-1753.
|
|
[35]LAMPERTICO P, VIGANOM, CHERONI C, et al.IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B[J].Hepatology, 2013, 57 (3) :890-896.
|
|
[36]SONNEVELD MJ, WONG VW, WOLTMAN AM, et al.Polymorphisms near IL28B and serologic response to peginterferon in HbeAg positive patients with chronic hepatitis B[J].Gastroenterology, 2012, 142 (2) :513-520.
|
DownLoad: